Lupin had got the nod in October, and said the drug had sales of around $66 mln in the US.
Ajantha Pharma also said it has already launched the product in the US market. Till date, it has launched 16 products in the US market.
“Clonidine Hydrochloride Extended Release Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 39 Abbreviated New Drug Applications (ANDAs) of which it has 22 final ANDA approvals, 2 tentative approvals, and 15 ANDAs under review with US FDA,” the Indian company said.
Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. It has over 6,500 employees for developing, manufacturing, and marketing drugs in over 30 countries.
For the financial year ended 31 st March, 2017, Ajanta’s consolidated revenue stood at Rs. 2,002 cr. (USD 305 million) and net profit stood at Rs. 507 cr. (USD 77 million).
Ajanta Pharma’s revenue has grown by 21% every year on average for the last five years, while net profit has grown by 46% every year on average.